Trial: 201908011

GOG 3031: [TESARO 4010-03-001] A PHASE 3, RANDOMIZED, DOUBLE-BLIND, MULTICENTER STUDY OF DOSTARLIMAB (TSR-042) PLUS CARBOPLATIN-PACLITAXEL VERSUS PLACEBO PLUS CARBOPLATIN-PACLITAXEL IN PATIENTS WITH RECURRENT OR PRIMARY ADVANCED ENDOMETRIAL CANCER (RUBY)

Phase

III

Principal Investigator

Powell, Matthew

Disease Site

Corpus Uteri

Learn more about this study at: clinicaltrials.gov